ArticleAnnals of biomedical engineering2024
Effect of Sinotubular Junction Size on TAVR Leaflet Thrombosis: A Fluid-Structure Interaction Analysis.
Article in Annals of biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Looking Beyond the Annulus: Why the Sinotubular Junction Matters in TAVR Planning.JACC. Case reports · 2026Article
- Fully coupled patient-specific fluid-structure interaction modeling of post-TAVI hemodynamics compared with echocardiographic measurements.Biomechanics and modeling in mechanobiology · 2026Article
- Two-Staged Transcatheter Aortic Valve Replacement in Severely Calcified Sinotubular Junction.JACC. Case reports · 2026Article
- Evolving capabilities of computed tomography imaging for transcatheter valvular heart interventions - new opportunities for precision medicine.The international journal of cardiovascular imaging · 2026Review
- Understanding the mechanisms of TAVI durability through computational modelling: a multidisciplinary review.European heart journal. Digital health · 2026Review
- Cardiac Computed Tomography in Structural Heart Interventions: From Preprocedural Planning to Procedural Strategy.Reviews in cardiovascular medicine · 2025Review
- Predicting procedural outcomes in transcatheter aortic valve implantation: a scoping review of numerical patient-specific simulations.Progress in biomedical engineering (Bristol, England) · 2025Article
- Article
- Assessing post-TAVR cardiac conduction abnormalities risk using an electromechanically coupled beating heart.Biomechanics and modeling in mechanobiology · 2025Article
- Benchtop Flow Stasis Quantification: In Vitro Methods and In Vivo Possibilities.Cardiovascular engineering and technology · 2024Article
- Thrombogenic Risk Assessment of Transcatheter Prosthetic Heart Valves Using a Fluid-Structure Interaction Approach.Computer methods and programs in biomedicine · 2024Article
Corrections and comments
- Update of
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
TAVR has emerged as a standard approach for treating severe aortic stenosis patients. However, it is associated with several clinical complications, including subclinical leaflet thrombosis characterized by Hypoattenuated Leaflet Thickening (HALT). A rigorous analysis of TAVR device thrombogenicity considering anatomical variations is essential for estimating this risk. Clinicians use the Sinotubular Junction (STJ) diameter for TAVR sizing, but there is a paucity of research on its influence on TAVR devices thrombogenicity. A Medtronic Evolut® TAVR device was deployed in three patient models with varying STJ diameters (26, 30, and 34 mm) to evaluate its impact on post-deployment hemodynamics and thrombogenicity, employing a novel computational framework combining prosthesis deployment and fluid-structure interaction analysis. The 30 mm STJ patient case exhibited the best hemodynamic performance: 5.94 mmHg mean transvalvular pressure gradient (TPG), 2.64 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.